Document is current
Any future updates will be listed below
-
Authors
Soerensen, Johannes Frasez https://orcid.org/0009-0000-0347-711X
Kristensen, Daniel Tuyet https://orcid.org/0000-0002-6753-7051
Ørskov, Andreas Due https://orcid.org/0000-0001-9996-7155
Hansen, Dennis Lund https://orcid.org/0000-0002-4478-1297
Aggerholm, Anni https://orcid.org/0000-0002-8915-0122
Grønbæk, Kirsten
Roug, Anne Stidsholt
Ludvigsen, Maja https://orcid.org/0000-0001-5089-3271
- License Information
-
More Information
Article History
Received: 23 June 2025
Revised: 29 August 2025
Accepted: 17 September 2025
First Online: 21 October 2025
Competing interests
: J.F.S.; A.D.R.; M.L.: No conflicts of interest to declare. D.T.K.: Consulting/advisory board: AbbVie, Astellas Pharma, Immedica pharma AB, Sevier; travel grants: Swedish Orphan Biovitrum; Research funding: unrestricted grant from Incyte Biosciences Nordic AB. A.S.R.: Jazz Pharmaceuticals: Travel grant, Daichii Sankyo: Consultancy fee, Immedica, Consultancy fee, unrestricted research grant, AbbVie: Consultancy fee. Servier: Consultancy fee. D.L.H.: Has served as Advisory Board member for Janssen and Takeda, Travel grants: EUSA Pharma, Alexion and SoBI outside this work. K.G.: Unrestricted research grants from Janssen Pharma and Medac. Not related to the current project.
: The study was approved by the Central Denmark Region Committees on Health Research Ethics (record no. 1-10-72-123-22) and conducted in accordance with Danish law. There was given exemption from informed consent in accordance with the Danish Health Care Act and the Decree on Information and Consent to Participation in Health Research Projects and on Reporting Supervision of Health Research Projects.
